García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, Nadal E, Rodriguez-Abreu D, Viñolas N, Massuti B
Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Coruña, Spain.
Medical Oncology Department, Hospital Universitario Nstra. Sra. de Valme, Seville, Spain.
Clin Transl Oncol. 2015 Dec;17(12):1020-9. doi: 10.1007/s12094-015-1455-z. Epub 2015 Dec 21.
Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87-108, 2015]. Non-small cell lung cancer (NSCLC) accounts for up to 85 % of all lung cancers. Multiple advances in the staging, diagnostic procedures, therapeutic options, as well as molecular knowledge have been achieved during the past years, although the overall outlook has not greatly changed for the majority of patients with the overall 5-year survival having marginally increased over the last decade from 15.7 to 17.4 % as reported by Howlader et al. (SEER Cancer Statistics Review 2015).
托雷等人（《CA：临床医师癌症杂志》65:87 - 108，2015年）报告称，肺癌是全球最常见的癌症，也是癌症相关死亡的主要原因。非小细胞肺癌（NSCLC）占所有肺癌的比例高达85%。在过去几年里，分期、诊断程序、治疗选择以及分子知识等方面都取得了多项进展，尽管大多数患者的总体前景并没有太大变化，据豪拉德等人（《监测、流行病学和最终结果癌症统计回顾2015》）报告，过去十年总体5年生存率仅从15.7%略微提高到17.4%。
Zotero 插件